Apitegromab
- Generic Name
- Apitegromab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2278276-46-1
- Unique Ingredient Identifier
- UZ54216N0Y
- Background
Apitegromab is under investigation in clinical trial NCT03921528 (An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy).
- Associated Conditions
- -
- Associated Therapies
- -
Scholar Rock's Phase 3 SAPPHIRE Study Of Apitegromab In SMA Meets Primary Goal; Stock Surges
Scholar Rock's Phase 3 SAPPHIRE study met primary goal, showing significant motor function improvement in SMA patients with apitegromab. The treatment was well-tolerated, with no new safety issues. The company plans to submit a U.S. BLA and EU MAA in Q1 2025.
Spinal Muscular Atrophy Clinical Trials 2024 (Updated): EMA
DelveInsight's 'Spinal Muscular Atrophy Pipeline Insight, 2024' report details 18+ companies developing 20+ therapies, including key players like Scholar Rock, Biogen, and Roche. The report covers clinical trials, MOA, ROA, recent developments, and emerging therapies like ACTX-401, Apitegromab, and GYM329, expected to impact the SMA market.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath